References
1. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain: H.F. Dovey, et al.; J. Neurochem. 76, 173 (2001).|2. The gamma-secretase inhibitor N--S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice: T.A. Lanz, et al.; J. Pharmacol. Exp. Ther. 305, 864 (2003).|3. Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD: K. Gowrishankar, et al.; J. Cell. Sci. 117, 4099 (2004).|4. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase: W.A. Campbell, et al.; J. Neurochem. 85, 1563 (2003).|5. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish: A. Geling, et al.; EMBO Rep. 3, 688 (2002).|6. The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling: T.Q. Crawford & H. Roelink; Dev. Dyn. 236, 886 (2007).|7. The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins: J. Kanungo, et al.; J. Neurochem. 106, 2236 (2008).|8. DAPT enhances the apoptosis of human tongue carcinoma cells: B.E. Grottklau, et al.; Int. J. Oral Sci. 1, 81 (2009).USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
